Skip to main content
iPS-cells-1

Insights

Medical Research July 24, 2018

Peering into reprogramming's black box, Stanford researchers ID critical stem cell creation protein

By Krista Conger

Stanford researchers identify a new protein that can fully substitute for one of the key "Yamanaka factors" to reprogram adult stem cells.

After about a decade and a half (or, gulp, more?) on the stem cell beat, I've written a lot about those developmentally flexible cells that are responsible for everything from generating a human embryo after fertilization to responding quickly and efficiently to developmental cues or SOS signals from damaged tissue. They're truly amazing cells, and we're still trying to figure out exactly what makes them tick.

The study of stem cells relies in large part on the discovery of a cellular reprogramming process that allows researchers to create what are called induced pluripotent stem cells, or iPS cells, from readily available cells like those in skin or blood. But the nuts and bolts of what happens during reprogramming remain somewhat mysterious.

Now microbiologist and immunologist Helen Blau, PhD, and postdoctoral scholar Thach Mai, PhD, have started to unveil the inner workings. They published their findings last week in Nature Cell Biology.

From my article:

The discovery creates a peephole into the black box of cellular reprogramming and may lead to new ways to generate iPS cells in the laboratory. It was made possible by the use of a unique laboratory model for reprogramming that tightly synchronizes the earliest steps of the process. 'This is a crucial regulator that would not have been discovered any other way,' said Helen Blau, PhD, professor of microbiology and immunology. 'It appears within two hours of the initiation of reprogramming, and then it's gone. But it's absolutely critical. If we eliminate it, reprogramming doesn't happen.'

The fact that reprogramming occurs at all in human cells captivated the world in 2007 when stem cell researcher Shinya Yamanaka, PhD, identified a panel of four proteins that, when applied externally to specialized cells like those from the skin or blood, could induce them to rewind their development and become stem cells. Since then, these four "Yamanaka factors" have been the cornerstone of decades of stem cell research.

Now Blau and Mai have shown that it's possible to replace one of the factors, Oct4, with another protein called NKX3-1. Cells exposed to NKX3-1 plus the three remaining factors reprogram as efficiently, and undergo the same molecular changes, as those exposed to the original four factors. Conversely, blocking the activity of NKX3-1 prevents any reprogramming by the Yamanaka factors. The researchers found that NKX3-1 is part of a cascade of reprogramming-specific events that are triggered within the cell by the external application of Oct4.

This discovery would not have been possible without a unique technique that synchronizes the first minutes and hours of reprogramming to allow for close study.

From our article:

In the new study, Mai fused human skin cells called fibroblasts to mouse embryonic stem cells. After fusion, factors in the developmentally flexible stem cell quickly and efficiently reprogrammed the fibroblast nucleus along a predictable, research-amenable timeline. The fused cells are called heterokaryons, and they enabled Mai and his colleagues to closely track patterns of gene expression and DNA modification during the first 24 hours of reprogramming.

The researchers have big plans for this heterokaryon model. According to Blau, who is the Donald E. and Delia B. Baxter Foundation Professor and director of the Baxter Foundation Laboratory for Stem Cell Biology:

Our goal is to study all facets of the regulatory logic, or 'grammar,' that underlies cellular reprogramming to pluripotency. Reprogramming completely changes a cell's fate. We want to understand the mechanistic and signaling pathways that mediate such a remarkable change.

Photo of iPS cells courtesy of Thach Mai

About Stanford Medicine

Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.

Krista-Conger

Science writer

Krista Conger

Senior science writer Krista Conger, PhD ’99, covers cancer, stem cells, dermatology, developmental biology, endocrinology, pathology, hematology, radiation oncology and LGBTQ+ issues for the office. She received her undergraduate degree in biochemistry at the University of California, Berkeley and her PhD in cancer biology from Stanford University. After completing the science writing program at UC Santa Cruz, she joined the Stanford Medicine Office of Communications in 2000. She enjoys distilling complicated scientific topics into engaging prose accessible to the layperson. Over the years, she has had chronicled nascent scientific discoveries from their inception to Food and Drug Administration approval and routine clinical use — documenting the wonder and long arc of medical research. Her writing has repeatedly been recognized with awards from the Counsel for the Advancement and Support of Education and the Association of American Medical Colleges. She is a member of the National Academy of Science Writers and a certified science editor through the Board of Editors in the Life Sciences. In her spare time, she enjoys textile arts, experimenting with new recipes and hiking in beautiful northwestern Montana, where she was raised and now lives.